Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "allergy"

44 News Found

Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics
People | September 15, 2022

Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics

He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets


Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US
News | August 31, 2022

Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US

This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US


USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
Drug Approval | May 12, 2022

USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19

Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19


Bayer posts higher sales, profit in first quarter
News | May 11, 2022

Bayer posts higher sales, profit in first quarter

Company's net income rose by 57.5 percent to 3.291 billion euros in Q1


GSK launches once daily, single inhaler-triple therapy for COPD patients
Drug Approval | April 26, 2022

GSK launches once daily, single inhaler-triple therapy for COPD patients

Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers


Novavax to participate in two booster studies using its COVID-19 vaccine
Biotech | March 26, 2022

Novavax to participate in two booster studies using its COVID-19 vaccine

U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines


Wockhardt’s novel antibiotic Phase 1 trial to be conducted by NIH, USA
Biotech | March 16, 2022

Wockhardt’s novel antibiotic Phase 1 trial to be conducted by NIH, USA

The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process


Moderna dosed the first participant for an experimental HIV trimer mRNA vaccine
News | March 14, 2022

Moderna dosed the first participant for an experimental HIV trimer mRNA vaccine

The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines


Johnson & Johnson Vision Care receives USFDA approval for drug-eluting contact lens
Drug Approval | March 06, 2022

Johnson & Johnson Vision Care receives USFDA approval for drug-eluting contact lens

Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category